Home>>Infectious Disease>> Viral Diseases>> HIV>>ONX-0914 TFA

ONX-0914 TFA Sale

(Synonyms: PR-957 TFA) 目录号 : GC62210

A selective inhibitor of the β5i (LMP7) subunit of the immunoproteasome

ONX-0914 TFA Chemical Structure

规格 价格 库存 购买数量
10mM*1 mL
¥1,305.00
现货
5 mg
¥855.00
现货
10 mg
¥1,440.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

The immunoproteasome is a specialized, inducible proteasome that generates peptides presented on major histocompatibility complex (MHC) class I molecules to cytotoxic T cells. Stimulation of cells with inflammatory cytokines such as IFN-γ leads to the replacement of constitutive catalytic proteasome β subunits with inducible β subunits (β1i (LMP2), β2i (MECL1), and β5i (LMP7)), which are required for the production of certain MHC class I-restricted T cell epitopes. ONX 0914 is a selective inhibitor of the β5i (LMP7) subunit of the immunoproteasome (IC50s = 65 and 73 nM for mouse and human, respectively) and demonstrates significantly weaker activity at the β5 subunit of the constitutive proteasome (IC50s = 0.92 and 1.04 ?M for mouse and human, respectively).1,2 It can block the production of IL-23 by activated monocytes and the production of IFN-γ and IL-2 by T cells.1 ONX 0914 can also inhibit IL-17-producing T cells under TH17-polarizing conditions in vitro and reduce TH1 and TH17 cell differentiation in vivo.3 This compound has been shown to attenuate disease progression in several experimental models of autoimmune disorders as well as in some hematologic malignancies.1,4,5,6

1.Muchamuel, T., Basler, M., Aujay, M.A., et al.A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritisNat. Med.15(7)781-787(2009) 2.Huber, E.M., Basler, M., Schwab, R., et al.Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificityCell148(4)727-738(2012) 3.Kalim, K.W., Basler, M., Kirk, C.J., et al.Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiationJ. Immunol.189(8)4182-4193(2012) 4.Basler, M., Daiee, M., Moll, C., et al.Prevention of experimental colitis by a selective inhibitor of the immunoproteasomeJ. Immunol.185(1)634-641(2010) 5.Niewerth, D., Franke, N.E., Jansen, G., et al.Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitorsHaematologica98(12)1896-1904(2013) 6.Niewerth, D., Kaspers, G.J., Assaraf, Y.G., et al.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell linesJ. Hematol. Oncol.7(1)1-15(2014)

Chemical Properties

Cas No. SDF
别名 PR-957 TFA
分子式 C33H41F3N4O9 分子量 694.7
溶解度 DMSO : 100 mg/mL (143.95 mM; Need ultrasonic) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.4395 mL 7.1974 mL 14.3947 mL
5 mM 0.2879 mL 1.4395 mL 2.8789 mL
10 mM 0.1439 mL 0.7197 mL 1.4395 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置